- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Therapy of Non-Hodgkin's Lymphoma - October 2002
National Cancer Institute®
Last Modified: October 1, 2002
- Malignant lymphoma of bone.
- Unusual implantation site of a port-a-cath system via the right femoral vein.
- [Clinical analysis of autologous peripheral blood stem cell transplantation in 182 patients with non-Hodgkin's lymphoma]
- Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori.
- Serum levels of soluble ICAM-1 in patients with malignant lymphoma in association with treatment response.
- [Non-Hodgkin lymphoma]
- [Radiotherapy of MALT-lymphoma of the stomach]
- Mycosis fungoides involving the oral cavity.
- Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.
- Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II
- Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for
- Primary mediastinal large B-cell lymphoma.
- Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
- Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infant.
- [Treatment of Hodgkin's lymphoma and hematopoietic cell autotransplantation]
- Clinical characteristics and treatment outcome of 218 patients with non-Hodgkin's lymphoma in a Singaporean institution.
- Primary breast lymphoma successfully treated with combination therapy including local radiation therapy: a report of two cases.
- Treatment of childhood mycosis fungoides with topical PUVA.
- First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori.
- Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
- Anti-CD20-based therapy of B cell lymphoma: state of the art.
- Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
- Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
- Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive
- Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after
- Fornix and conjunctiva reconstruction by amniotic membrane in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma.
- Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease.
- Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
- [The impact of chemotherapy on haematological and biochemical profiles during malignant blood diseases in Abidjan, Cote d'Ivoire]
- Lymphoma of the cervix. Imaging and transcatheter arterial embolization.
- Spontaneous regression and recurrence of primary low-grade B-cell gastric lymphoma on the gastric stump 15 and 20 years after
- Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Table of Contents
1
UI - 11995873
AU - Durr HR; Muller PE; Hiller E; Maier M; Baur A; Jansson V; Refior HJ
TI -
Malignant lymphoma of bone.
SO - Arch Orthop Trauma Surg 2002 Feb;122(1):10-6
AD - Department of Orthopaedics and Orthopaedic Surgery, University of
Rostock, Germany. hans_roland.duerr@med.uni-rostock.de
Malignant lymphoma of bone is rare. In many cases, its diagnosis is
delayed because of unspecific clinical signs and equivocal radiographs.
Therapy in general is multimodal, including surgery and radio- and
chemotherapy. Our objective was to demonstrate the clinical and
radiological aspects of the lesion to optimize diagnostic approaches and
to evaluate treatment and prognostic factors. Thirty-six patients with
malignant lymphoma of bone who were surgically treated over a
15-year-period were retrospectively reviewed. Seventeen of them showed a
singular bone non-Hodgkin's lymphoma (NHL) which was classified as
primary lymphoma of the bone (PLB). In 13 cases, dissemination of the
disease with multiple bone or visceral involvement was apparent (dNHL).
Six patients suffered from bone involvement due to Hodgkin's disease
(HD). Surgical treatment was indicated for diagnostic reasons or
complications due to the disease. Radiation and chemotherapy were part
of the oncological treatment. The patients' mean age was 57 years.The
main symptom in malignant bone lymphoma in 33 patients was pain, with an
average duration of 8 months. In the secondary cases, bone involvement
appeared on average 57 months after the initial diagnosis. An osteolytic
pattern was seen in 58% of the lesions. Soft-tissue involvement was seen
in 71% of cases (PLB 80%, dNHL 73%, HD 40%) and was the primary
diagnostic sign associated with this disease. The 5-year survival rate
was 61% (PLB 88%, dNHL 38%, HD 50%). Multiple vs solitary bone
involvement was the most significant factor in the prognosis.
Extraskeletal involvement significantly decreased survival. No
correlation was found between gender, age, location, or histological
subtypes and survival. Bone involvement in NHL appears late in the
extraskeletal disease. The clinical appearance is nonspecific, and the
delay between the onset of symptoms and diagnosis is often long. One of
the major radiologic signs is the existence of a soft-tissue tumor
surrounding the bone with little or no bone involvement on plain films.
Treatment generally is conservative, based on the stage of the disease.
Local radiation with or without systemic chemotherapy should be used.
The long-term survival is favorable, but dependent on the stage of the
disease and the amount of bone involvement.
2
UI - 12136255
AU - Meyer F; Buerger T; Gebauer T; Halloul Z
TI -
Unusual implantation site of a port-a-cath system via the right femoral
vein.
SO - J Cancer Res Clin Oncol 2002 Jul;128(7):400-1
AD - Department of Surgery, University Hospital, Otto von Guericke University
Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Frank.Meyer@Medizin.Uni-Magdeburg.de
3
UI - 12137594
AU - Liu K; Lu D
TI -
[Clinical analysis of autologous peripheral blood stem cell
transplantation in 182 patients with non-Hodgkin's lymphoma]
SO - Zhonghua Nei Ke Za Zhi 2002 Jun;41(6):363-6
AD - Peiking University Institute of Hematology, Beijing 100044,China.
kaiyanliu@mail.china.com
OBJECTIVE: To evaluate the efficacy of autologous peripheral blood stem
cell transplantation (APBSCT) in patients with non-Hodgkin's lymphoma.
METHODS: 182 patients with non-Hodgkin's lymphoma were enrolled in a
clinical study carried out in 34 hospitals of China. Before APBSCT 112
patients were in first completely remission (CR(1)) and 70 patients in
partial remission (PR) or relapse. Autologous peripheral blood stem cell
(APBSC) mobilized by high-dose cyclophosphamide (HD-CY)(n = 55),
high-dose Ara-C (HD-Ara-C)(n = 7), increased dose CY based regimens with
G-CSF (n = 102) and G-CSF only (n = 18). 112 patients in CR(1) received
high-dose chemotherapy with (n = 39) or without total body irradiation
(TBI) (n = 73). 70 patients in PR or relapse received high-dose
chemotherapy with (n = 29) or without TBI (n = 41). RESULTS: Median time
for hemotopoeitic recovery of WBC >/= 1.0 x 10(9)/L, and platelets >/=
2.0 x 10(9)/L was 12 (10 approximately 30) days and 12(0 approximately
181) days respectively. After a median follow-up of 24 months, the
probability of 3-year disease free survival (DFS) in CR(1) and in PR or
relapse was 69. 7% and 44.9% respectively. The probability of 3-year
overall survival (OS) and DFS for patients in CR(1) group was 76.2% and
70.1% following high-dose chemotherapy with TBI and 78.4% and 68.0%
following high-dose chemotherapy without TBI. However, the probability
of 3-year OS and DFS for patients in PR or relapse group was 76.5% and
57.5% following high-dose chemotherapy with TBI and 58.4% and 40.1%
following high-dose chemotherapy without TBI. After transplantation, 18
patients were died of original disease (16.1%) in CR(1) group and 19
patients (27.1%) in PR or relapse group. Transplant-related mortality
was 2.6%. CONCLUSION: A PBSCT is a safe and efficacious therapeutic
measure in patients with NHL.
4
UI - 12241663
AU - Fischbach W; Goebeler-Kolve M; Starostik P; Greiner A; Muller-Hermelink
TI -
HK
Minimal residual low-grade gastric MALT-type lymphoma after eradication
of Helicobacter pylori.
SO - Lancet 2002 Aug 17;360(9332):547-8
AD - Department of Internal Medicine II, Klinikum Aschaffenburg, 63739
Aschaffenburg, Germany. wolfgang.fischback@klinikum-aschaffenbug.de
Helicobacter pylori eradication is the initial treatment of choice in
localised low-grade gastric MALT (mucosa-associated
lymphoid-tissue)-type lymphoma. We describe the natural course of seven
patients who refused further oncological treatment for persistent
lymphoma after successful eradication of H pylori. Despite persistent
clonality, neither lymphoma progression nor high-grade transformation
arose during a mean observation period of 34 (range 22-44) months. In
view of the favourable course of these patients, a watch-and-wait
strategy could be a valid approach to management of this disease.
5
UI - 8790163
AU - Musolino C; Alonci A; Allegra A; Spatari G; Bellomo G; Quartarone M
TI -
Serum levels of soluble ICAM-1 in patients with malignant lymphoma in
association with treatment response.
SO - Br J Haematol 1996 Sep;94(3):580-1
6
UI - 12371400
AU - Bol P
TI -
[Non-Hodgkin lymphoma]
SO - Ned Tijdschr Tandheelkd 2002 Jul;109(7):267-8
AD - Faculteit Civiele Techniek en Geowetenschappen, Sectie
Gezondheidstechniek, Delft, Netherlands. pbol2xs4all.nl
7
UI - 12152534
AU - Szekely J; Petranyi A; Glavak C; Schneider T; Rosta A; Esik O
TI -
[Radiotherapy of MALT-lymphoma of the stomach]
SO - Orv Hetil 2002 Jul 14;143(28):1683-9
AD - Orszagos Onkologiai intezet, Sugarterapias Osztaly, Budapest.
szekely@oncol.hu
INTRODUCTION: The stomach is the most common extranodal site of the
low-grade MALT lymphoma. This lymphoma usually appears in elderly
patients, with typically indolent signs. At the time of the diagnosis,
the lymphoma is usually localized in the stomach and/or the adjacent
lymph nodes. The choice in these cases is local treatment, which in the
past involved only a surgical approach (total/partial gastrectomy),
whereas more recently radiotherapy is preferred. PURPOSE: The radiation
fields cover the whole stomach and the paragastric lymph nodes. The
radiation doses range from 30 to 40 Gy, given in 1.5 Gy fractions 5 days
a week. An adequate dose distribution to the target volume can be
achieved by 3D treatment planning and conformal irradiation. METHODS: At
our institute, 5 patients were treated with this method, the intention
was curative in 3 cases, and palliative in 2 cases. The median dose in
the 4 cases completed as initially planned was 33.6 Gy, delivered at 1.5
Gy per fraction. The adjacent critical organs do not exceed the
tolerance doses by this method. RESULTS: In these 4 cases, complete
regression was achieved, as determined by endoscopy and biopsy. In the
fifth, locally advanced case, irradiation had to be terminated because
of gastric bleeding. During irradiation, no other severe acute
side-effects were detected. CONCLUSION: The literature and our
preliminary results confirm that radiation therapy for early, localized
MALT lymphoma of the stomach, or in disseminated cases, can be not only
effective and safe, but offers the significant advantages of low
treatment-related morbidity and preservation of the gastric function.
8
UI - 12196250
AU - Chua MS; Veness MJ
TI -
Mycosis fungoides involving the oral cavity.
SO - Australas Radiol 2002 Sep;46(3):336-9
AD - Department of Radiation Oncology, Westmead Hospital, Sydney, Australia.
Mycosis fungoides is a malignant T-cell lymphoproliferative disease with
a predilection for cutaneous involvement. Extracutaneous disease is
uncommon and oral mucosal involvement is rare. We describe a case of
mycosis fungoides involving the hard palate treated with radiotherapy.
The relevant literature on this topic is reviewed.
9
UI - 12224972
AU - Suchin KR; Junkins-Hopkins JM; Rook AH
TI -
Treatment of stage IA cutaneous T-Cell lymphoma with topical application
of the immune response modifier imiquimod.
SO - Arch Dermatol 2002 Sep;138(9):1137-9
AD - Department of Dermatology, Hospital of the University of Pennsylvania, 2
Rhoads Pavilion, 3600 Spruce St, Philadelphia, PA 19104-2399, USA.
arook@mail.med.upenn.edu
10
UI - 12228207
AU - Jager G; Neumeister P; Brezinschek R; Hinterleitner T; Fiebiger W; Penz
TI -
M; Neumann HJ; Mlineritsch B; DeSantis M; Quehenberger F; Chott A;
Beham-Schmid C; Hofler G; Linkesch W; Raderer M
Treatment of extranodal marginal zone B-cell lymphoma of
mucosa-associated lymphoid tissue type with cladribine: a phase II
study.
SO - J Clin Oncol 2002 Sep 15;20(18):3872-7
AD - Division of Hematology, Division of Gastroenterology, Institute of
Medical Informatics, Statistics and Documentation, Karl-Franzens
University of Graz, Graz, Austria. gerald.jaeger@kfunigraz.ac.at
PURPOSE: As chemotherapy has not been extensively studied in patients
with lymphoma of the mucosa-associated lymphoid tissue (MALT), we
initiated a prospective study to evaluate the activity of the nucleoside
analog cladribine (2-chlorodeoxyadenosine [2-CdA]) in this disease.
PATIENTS AND METHODS: Patients with histologically verified MALT-type
lymphoma were enrolled. 2-CdA was administered at a dose of 0.12 mg/kg
body weight on 5 consecutive days, as a 2-hour infusion. Cycles were
repeated every 4 weeks for a maximum of six cycles. RESULTS: Nineteen
patients with gastric and seven patients with extragastric MALT lymphoma
were enrolled. All patients were chemotherapy-naive, and two had been
locally irradiated before systemic relapse of the lymphoma. A total of
102 cycles was administered to our patients (median number of cycles per
patient, four). All 25 assessable patients responded to treatment: 21
patients (84%) achieved complete remission (CR) and four patients
achieved partial remission. All patients (100%) with gastric
presentation, but only three patients (43%) with extragastric
presentation, achieved CR. Toxicities were moderate and mainly
hematologic and required dose reduction and/or premature discontinuation
of therapy in only three cases. Two patients died from vascular events,
one shortly after the first cycle because of myocardial infarction and
the other from stroke 3 months after the second course. Three patients
relapsed after 13, 18, and 22 months and one patient showed progressive
disease after 15 months. At present, 24 patients are alive at a median
follow-up time of 32 months. CONCLUSION: Our data demonstrate that 2-CdA
is highly effective in inducing CR in 84% of patients with MALT-type
lymphoma.
11
UI - 12228209
AU - Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
TI -
Subsequent chemotherapy regimens are well tolerated after
radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for
non-Hodgkin's lymphoma.
SO - J Clin Oncol 2002 Sep 15;20(18):3885-90
AD - Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN
55905, USA. ansell.stephen@mayo.edu
PURPOSE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC
Pharmaceutical, San Diego, CA) is an effective therapy for patients with
relapsed B-cell non-Hodgkin's lymphoma. The predominant toxicity of 90Y
ibritumomab tiuxetan has been myelosuppression, and concern has been
expressed about the tolerability of further treatment after this
therapy. The goal of this analysis was to evaluate the therapy given to
patients who relapsed after 90Y ibritumomab tiuxetan. PATIENTS AND
METHODS: A retrospective analysis was performed on 58 patients treated
at a single institution on five separate protocols that used 90Y
ibritumomab tiuxetan 0.4 mCi/kg. All patients had experienced disease
progression after 90Y ibritumomab tiuxetan treatment and received
subsequent therapy. The toxicity seen in this cohort of patients with
subsequent treatment regimens was analyzed and compared with that of
control groups who did not receive 90Y ibritumomab tiuxetan. RESULTS:
The median number of subsequent therapies was two (range, one to seven).
Sixteen (28%) of the 58 patients received growth factor support with
subsequent chemotherapy, and two patients were treated with reduced
doses because of persistent pancytopenia. Eight patients subsequently
had an autologous stem-cell transplantation with stem cells collected
after 90Y ibritumomab tiuxetan therapy. Excluding patients hospitalized
at the time of transplantation, 13 patients were hospitalized for
neutropenic fever, thrombocytopenia, or both. When compared to patients
who did not receive 90Y ibritumomab tiuxetan, there was no significant
difference in toxicity. CONCLUSION: We conclude that chemotherapy or
autologous stem-cell transplantation after prior therapy with 90Y
ibritumomab tiuxetan is feasible and reasonably well tolerated. The
toxicity with subsequent therapy seems similar to that in patients not
treated with 90Y ibritumomab tiuxetan.
12
UI - 12356098
AU - Ergul SM; Lal A; Afri L; Frei-Lahr D
TI -
Primary mediastinal large B-cell lymphoma.
SO - South Med J 2002 Sep;95(9):1005-7
AD - Department of Medicine, Medical University of South Carolina,
Charleston, USA.
Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct disease
entity that has a relatively short history. The prognosis and therapy of
patients with PMLBCL is still controversial. We summarize our experience
with PMLBCL at the Medical University of South Carolina between 1997 and
2000.
13
UI - 12006543
AU - Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
TI -
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells:
relevance to mechanism of therapeutic action.
SO - Clin Cancer Res 2002 May;8(5):1234-40
AD - Department of Dermatology, The University of Texas M.D. Anderson Cancer
Center, Houston 77030, USA.
PURPOSE: Bexarotene is the first synthetic rexinoid approved for the
treatment of all stages of cutaneous T-cell lymphoma (CTCL) however the
mechanism of bexarotene action is unknown. We examined the effects of
bexarotene on induction of apoptosis and expression of its cognate
receptors in well-established CTCL cell lines (MJ, Hut78, and HH).
EXPERIMENTAL DESIGN: CTCL cells were treated with 0.1, 1, and 10 microM
bexarotene for 24, 48, 72, and 96 h. Apoptosis was determined by
flow-cytometry analysis of sub-G(1) hypodiploid nuclei and annexin V
binding populations. Apoptosis-associated proteins and retinoid
receptors were detected by Western blots. RESULTS: Bexarotene treatment
at 1 and 10 microM for 96 h increased the number of cells with sub-G1
populations and annexin V binding in a dose-dependent manner compared
with vehicle controls (DMSO) in all three cell lines, respectively.
Bexarotene treatment suppressed the expression of retinoid X receptor
alpha and retinoic acid receptor alpha proteins in all three lines
compared with untreated controls. Bexarotene treatment decreased the
protein levels of survivin, activated caspase-3, and cleaved
poly(ADP-Ribose) polymerase, but had no obvious effect on expression of
Fas/Fas ligand and bcl-2 proteins in all three CTCL lines. CONCLUSIONS:
Bexarotene treatment at clinically relevant concentrations causes
apoptosis of CTCL cell lines in association with activation of caspase-3
and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation
of retinoid X receptor alpha, retinoic acid receptor alpha, and
survivin. These findings support apoptosis as a mechanism for bexarotene
therapy in CTCL.
14
UI - 12150131
AU - Trupiano JK; Bringelsen K; Hsi ED
TI -
Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old
infant.
SO - J Cutan Pathol 2002 Feb;29(2):107-12
AD - Department of Pathology, Cleveland Clinic Foundation, OH 44195, USA.
BACKGROUND: We report a case of primary cutaneous lymphoblastic lymphoma
(LBL) presenting in an 8-week-old infant. METHODS: Histopathology and
flow cytometric analysis confirmed the diagnosis of a lymphoblastic
lymphoma. The cells expressed CD19, CD20, CD34 and surface
immunoglobulin (sIg). RESULTS: The cells were negative for TdT and CD99.
This unusual immunophenotype has been described as "transitional
pre-B-cell", in that the cells express both immature markers (CD34) and
mature markers (sIg). CONCLUSIONS: To our knowledge, only five other
cases of sIg positive precursor B-cell LBL have been reported in the
literature. This may represent the youngest reported case of primary
cutaneous LBL, occurring at 8weeks of age.
15
UI - 11921529
AU - Delgado Lamas JL
TI -
[Treatment of Hodgkin's lymphoma and hematopoietic cell
autotransplantation]
SO - Rev Invest Clin 2001 Nov-Dec;53(6):552-60
AD - Division Medicina Interna Hospital de Especialidades, Centro Medico
Nacional de Occidente, IMSS, Guadalajara, Jalisco.
16
UI - 11063195
AU - Lee SC; Wong JE; Kueh YK
TI -
Clinical characteristics and treatment outcome of 218 patients with
non-Hodgkin's lymphoma in a Singaporean institution.
SO - Singapore Med J 2000 Mar;41(3):118-21
AD - Department of Medical Oncology, National University Hospital, Singapore.
A retrospective analysis of 218 patients with non-Hodgkin's lymphoma
(NHL) seen at a single institution in Singapore over a ten-year period
was conducted. Twenty percent, 56% and 24% of patients had low-,
intermediate- and high-grade disease respectively using the Working
Formulation, and 25% of patients immunophenotyped had T-cell NHL.
Forty-nine percent had primary extranodal disease, with the commonest
sites of involvement being the gastrointestinal tract, nasal cavity, and
tonsils. 86% and 73% respectively of patients with intermediate and high
grade disease received combination chemotherapy as first line treatment,
with CHOP being the most commonly used regime. Seventy-four percent of
patients with low grade lymphoma received first line chemotherapy, 5%
each was treated with radiotherapy or surgery alone, and 21% was treated
symptomatically. Patients with low grade B-cell lymphoma had a 5-year
survival of 80% and 10-year survival of 42%. One-year survival for
intermediate and high grade B-cell lymphoma was 76% and 42%, while
2-year survival was 67% and 42% respectively. 1-, 2-, and 3-year
survival for patients with T-cell lymphoma was 67%, 46% and 37%
respectively. The difference in survival between low-, intermediate- and
high-grade B-cell lymphoma was statistically significant (p = 0.0018
using the log rank test), but that between B- and T-cell lymphoma was
not. Using the Cox regression model, International prognostic index,
grade and extranodal disease were found to be statistically significant
predictors of survival (p = 0.0001, p = 0.0157, p = 0.0343)
respectively.
17
UI - 12002602
AU - Suzuki Y; Ito J; Hasegawa M; Katano S; Saito J; Ito H
TI -
Primary breast lymphoma successfully treated with combination therapy
including local radiation therapy: a report of two cases.
SO - Radiat Med 2002 Jan-Feb;20(1):37-9
AD - Department of Radiology, Maebashi Red Cross Hospital, Japan.
Recently, a combination of local irradiation and chemotherapy has been
suggested as a standardized treatment for localized lymphoma. However,
it has been difficult to establish a standard treatment for localized
primary breast lymphoma simply because of its rarity. We report two
cases of primary breast lymphoma successfully treated with a combination
therapy including local radiation therapy. A 46-year-old woman with
stage I primary breast lymphoma was irradiated with 30 Gy to the
involved breast by 4 MV X-rays and 9 Gy to the involved field by
electron beam after tumorectomy. Then three cycles of CHOP therapy were
performed. She has been well and has shown no evidence of disease for 58
months. A 72-year-old woman with stage II primary breast lymphoma was
treated with three cycles of CHOP therapy followed by irradiation with
40 Gy per breast by 4 MV X-rays. She is well and has been disease-free
for 49 months. We suggest that a combination of local irradiation and
short course of chemotherapy can be useful in the treatment of primary
breast lymphoma.
18
UI - 12271301
AU - Pabsch H; Rutten A; Von Stemm A; Meigel W; Sander CA; Schaller J
TI -
Treatment of childhood mycosis fungoides with topical PUVA.
SO - J Am Acad Dermatol 2002 Oct;47(4):557-61
AD - Department of Dermatology, Dermatohistological Unit, St Barbara
Hospital, Duisburg, Germany.
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma,
which is usually observed in mid to late adulthood. We report 5 cases of
mycosis fungoides in children, all presenting as patch- and plaque-stage
disease most commonly involving the buttocks. Histologic examination
showed in every case the typical features of mycosis fungoides. In 4 of
the 5 cases, the infiltrating lymphocytes were characterized by the
T-cell phenotype CD3(+), CD4(+), CD8(+); and in 3 cases, a monoclonal
rearrangement of the T-cell receptor gamma (TCR-gamma) gene was found.
Three children received topical PUVA treatment, and the other two were
treated with mid-potency topical corticosteroids, resulting in complete
clinical remission. A management approach to mycosis fungoides with
topical PUVA may be appropriate for children.
19
UI - 11665693
AU - Timm S; Sailer M; Fuchs KH; Greiner A
TI -
First successful treatment of a primary high-grade gastric MALT lymphoma
by eradication therapy for Helicobacter pylori.
SO - Gastroenterology 2001 Oct;121(4):1025-6
20
UI - 12200356
AU - Spina M; Gabarre J; Rossi G; Fasan M; Schiantarelli C; Nigra E; Mena M;
TI -
Antinori A; Ammassari A; Talamini R; Vaccher E; di Gennaro G; Tirelli U
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin
disease and HIV infection.
SO - Blood 2002 Sep 15;100(6):1984-8
AD - Division of Medical Oncology A, National Cancer Institute, Via
Pedemontana Occidentale 12, 33081 Aviano (PN), Italy.
A phase 2 prospective study was performed to evaluate the feasibility
and activity of a short, dose-intensive chemotherapy regimen and
radiotherapy (the Stanford V regimen) plus highly active antiretroviral
therapy (HAART) and granulocyte colony-stimulating factor (G-CSF)
support in patients with Hodgkin disease and HIV infection. Fifty-nine
patients were enrolled. Stanford V was well tolerated and 69% of the
patients completed treatment with no dose reduction or delayed
chemotherapy administration. The most important dose-limiting side
effects were bone marrow toxicity and neurotoxicity. Complete remission
was achieved by 81% of the patients, and after a median follow-up of 17
months 33 patients (56%) were alive and disease-free. The estimated
3-year overall survival (OS), disease-free survival (DFS), and freedom
from progression (FFP) were 51%, 68%, and 60%, respectively. Probability
of FFP was significantly (P =.02) higher among patients with an
International Prognostic Score (IPS) of 2 or lower than in those with an
IPS higher than 2, and the percentages of FFP at 2 years in these groups
were 83% and 41%, respectively. Similarly, the probability of OS was
significantly (P =.0004) different in the 2 groups, and the percentages
of OS at 3 years were 76% and 33%, respectively. Our data confirm that
the Stanford V regimen with concomitant HAART is feasible and active in
an HIV setting. However, a more intensive approach should be considered
in patients with high IPSs.
21
UI - 12357351
AU - Kosmas C; Stamatopoulos K; Stavroyianni N; Tsavaris N; Papadaki T
TI -
Anti-CD20-based therapy of B cell lymphoma: state of the art.
SO - Leukemia 2002 Oct;16(10):2004-15
AD - Department of Medicine, 2nd Division of Medical Oncology, Metaxa Cancer
Hospital, Piraeus, Greece.
Over the last 5 years, studies applying the chimeric anti-CD20 MAb have
renewed enthusiasm and triggered world-wide application of anti-CD20
MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native
chimeric anti-CD20 and isotope-labeled murine anti-CD20 MAbs are
currently employed with encouraging results as monotherapy or in
combination with conventional chemotherapy and in consolidation of
remission after treatments with curative intent (ie after/ in
combination with high-dose chemotherapy and hematopoietic stem cell
rescue). On the available experience, anti-CD20 MAb-based therapeutic
strategies will be increasingly integrated in the treatment of B cell
NHL and related malignancies.
22
UI - 12377971
AU - Hainsworth JD; Litchy S; Burris HA 3rd; Scullin DC Jr; Corso SW; Yardley
TI -
DA; Morrissey L; Greco FA
Rituximab as first-line and maintenance therapy for patients with
indolent non-hodgkin's lymphoma.
SO - J Clin Oncol 2002 Oct 15;20(20):4261-7
AD - Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited
Liability Corporation, Nashville, TN, USA. jhainsworth@tnonc.com
PURPOSE: To evaluate response to single-agent rituximab in patients with
indolent non-Hodgkin's lymphoma (NHL) and no previous systemic therapy,
and the feasibility, toxicity, and efficacy of maintenance rituximab,
administered at 6-month intervals, in patients with objective response
or stable disease after first-line rituximab therapy. PATIENTS AND
METHODS: Patients with indolent NHL (follicular or small lymphocytic
subtypes) previously untreated with systemic therapy received rituximab
375 mg/m(2) intravenously weekly for 4 weeks. Patients were restaged at
week 6 for response; those with objective response or stable disease
received maintenance rituximab courses (identical dose and schedule) at
6-month intervals. Maintenance was continued for a maximum of four
62 patients were entered onto this trial; minimum follow-up was 24
months. RESULTS: Sixty patients (97%) completed the first 4-week course
of rituximab and were assessable for response. All have now completed
rituximab therapy; 36 (58%) received four courses at 6-month intervals.
The objective response rate at 6 weeks was 47%; 45% of patients had
stable disease. With continued maintenance, final response rate
increased to 73%, with 37% complete responses. Response was similar in
patients with follicular versus small lymphocytic subtypes (76% v 70%,
respectively). Median actuarial progression-free survival was 34 months.
Two patients experienced grade 3/4 toxicity with the first dose; one
patient was removed from treatment. No cumulative or additional
toxicities were seen with maintenance courses. CONCLUSION: Rituximab is
highly active and extremely well tolerated as first-line single-agent
therapy for indolent NHL. First-line treatment with scheduled
maintenance at 6-month intervals produces high overall and complete
response rates and a longer progression-free survival (34 months) than
has been reported with a standard 4-week treatment.
23
UI - 12209749
AU - Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi
TI -
E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet
light A in patients with cutaneous T-cell lymphoma.
SO - Cancer 2002 Aug 1;95(3):569-75
AD - Division of Medical Oncology, Azienda Ospedaliera-Universita, Via
Giustiniani 2, 35123 Padua, Italy. mgaliz@tiscalinet.it
PURPOSE: To evaluate the efficacy and side effects of psolaren with
ultraviolet light A (PUVA) and interferon-alpha-2a (IFN-alpha-2a) in
patients with mycosis fungoides (MF) and Sezary syndrome (SS). PATIENTS
all stages of MF and SS were treated in a prospective Phase II trial
with systemic escalating doses of IFN-alpha-2a combined with PUVA for 1
year, followed by indefinite PUVA maintenance in complete responding
patients. RESULTS: Sixty-three patients were enrolled (Stage IA, n = 6;
IB, n = 37; IIA, n = 3; IIB, n = 3; III, n = 12; IVA, n = 2). Ten
patients had received previous therapy. The median follow-up duration
for the entire cohort is 37 months. Of 63 patients, 51 achieved a
complete response (CR; 74.6%) or partial response (PR; 6%) to therapy.
The median response duration is 32 months. The 5-year overall survival
rate is 91% and the 5-year disease-free survival rate is 75%. No
life-threatening side effects were observed. Five patients stopped
IFN-alpha-2a therapy due to toxicity. Eighty-four percent of the
patients received more than 75% of the planned dose (12 million units
three times a week). CONCLUSIONS: This combination of IFN-alpha-2a and
phototherapy is an effective and safe therapy for patients with
symptomatic MF. Copyright 2002 American Cancer Society.
24
UI - 12209750
AU - Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
TI -
Prophylactic intrathecal methotrexate and hydrocortisone reduces central
nervous system recurrence and improves survival in aggressive
non-hodgkin lymphoma.
SO - Cancer 2002 Aug 1;95(3):576-80
AD - First Department of Internal Medicine, Yokohama City University School
of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-004, Japan.
cavalier@ch-yamate.dienet.com
BACKGROUND: Central nervous system (CNS) recurrence is almost invariably
fatal in patients with aggressive non-Hodgkin lymphoma (NHL). Although
some protocols are intended to prevent CNS disease, the value of CNS
prophylaxis in patients with aggressive NHL remains to be determined.
METHODS: We retrospectively analyzed a cohort of 68 adults with NHL who
had been treated uniformly with systemic chemotherapy and had attained
complete remission (CR) of disease. Patients ranged in age from 15 to 77
years (median, 56 years). Median follow-up after CR was 40 months. After
CR was attained, 29 patients (Group A) received CNS prophylaxis
consisting of four doses of intrathecal methotrexate 10 mg/m(2) and
hydrocortisone 15 mg/m(2) as soon as they could tolerate it. The other
39 patients (Group B) did not receive CNS prophylaxis. RESULTS: Although
bulky mass (45% vs. 21%, P = 0.03) was more frequent in Group A than in
Group B, none of the patients in Group A experienced CNS recurrence
(0%), whereas CNS recurrence occurred in six patients in Group B (15%).
This difference was significant (P = 0.03). Multivariate logistic
regression analysis for CNS recurrence identified no CNS prophylaxis (P
= 0.01) and bone marrow involvement (P = 0.02) as independent
predictors. Among patients without CNS disease, systemic recurrence
occurred in 5 patients in Group A and in 11 patients in Group B (P =
0.12). The 5-year overall survival rate from CR was 80% in Group A and
58% in Group B (P = 0.05). The 5-year recurrence-free survival rate from
CR was 85% in Group A and 51% in Group B (P = 0.01). CONCLUSIONS:
Prophylactic intrathecal methotrexate and hydrocortisone injection
reduces the incidence of CNS recurrence following CR in patients with
aggressive NHL and improves the chance of long-term survival. Copyright
2002 American Cancer Society.
25
UI - 12352248
AU - Hisabe T; Imamura K; Furukawa K; Tsuda S; Matsui T; Yao T; Kanda M;
TI -
Ohshima K; Kikuchi M
Regression of CD5-positive and Helicobacter pylori-negative
mucosa-associated lymphoid tissue lymphoma of the rectum after
administration of antibiotics: report of a case.
SO - Dis Colon Rectum 2002 Sep;45(9):1267-70
AD - Department of Internal Medicine, Tenyokai Chuo Hospital, Kagoshima City,
Japan.
We report a case of mucosa-associated lymphoid tissue lymphoma of the
rectum that regressed after antibiotics administration. A 70-year-old
female complained of abdominal discomfort. Colonoscopy performed in July
1998 showed a hemispheric protrusion of the rectum, the surface of which
was covered with normal rectal mucosa. Pathologic diagnosis of a biopsy
specimen was low-grade mucosa-associated lymphoid tissue lymphoma.
Gastroscopy showed multiple erosions of the antrum, and was negative by
both culture and histology. After informed consent the patient was
treated with a 14-day course of lansoprazole, amoxicillin, and
clarithromycin for the eradication of. Repeat colonoscopy ten days after
initiation of treatment showed that the rectal tumor had disappeared,
and this was confirmed by histologic examination. There was no
recurrence during 20 months of follow-up.
26
UI - 12063048
AU - Kobayashi A; Takahira M; Yamada A; Segawa Y; Tanahashi T; Shirao Y;
TI -
Nonomura A
Fornix and conjunctiva reconstruction by amniotic membrane in a patient
with conjunctival mucosa-associated lymphoid tissue lymphoma.
SO - Jpn J Ophthalmol 2002 May-Jun;46(3):346-8
AD - Department of Ophthalmology, Kanazawa University Graduate School of
Medical Science, Kanazawa, Ishikawa, Japan.
BACKGROUND: Conjunctival mucosa-associated lymphoid tissue (MALT)
lymphoma is a rare, low-grade, non-Hodgkin's B-cell lymphoma. Herein, we
report our successful management of the large conjunctival defect caused
by resection of conjunctival MALT lymphoma by covering it with
transplanted amniotic membrane. CASE: A 28-year-old Japanese man, who
had been diagnosed histologically as having conjunctival MALT lymphoma
in his left eye, was referred to us for treatment. The tumor was located
on the lower bulbar and palpebral conjunctiva, and involved the fornix.
Extensive resection of the conjunctival lesion was performed. Two pieces
of amniotic membrane were used to reconstruct the fornix, bulbar, and
palpebral conjunctival defect. OBSERVATIONS: Epithelialization over the
transplantation was completed within 3 weeks when all sutures were
removed. During the 6 months of follow-up, there was no recurrence or
any postoperative complication, such as graft rejection, symblepharon,
or chronic inflammation. CONCLUSIONS: We demonstrated for the first time
that amniotic membrane can be used to cover a large defect on both
bulbar and palpebral conjunctiva when such a low-grade malignancy as
MALT lymphoma is extensively excised. Amniotic membrane transplantation
was quite effective for the fornix and conjunctival reconstruction.
27
UI - 10975767
AU - Bayerdorffer E; Morgner A
TI -
Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid
tissue type: management of the disease.
SO - Dig Liver Dis 2000 Apr;32(3):192-4
AD - Medical Department I for Gastroenterology, Hematology, and Oncology,
Technical University of Dresden, Germany. bayerdoerffer@t-online.de
28
UI - 11000990
AU - Salles G; Coiffier B
TI -
Autologous peripheral blood stem cell transplantation for non-Hodgkin's
lymphoma.
SO - Baillieres Best Pract Res Clin Haematol 1999 Mar-Jun;12(1-2):151-69
AD - Service d'Hematologie--Universite Lyon I, Centre Hospitalier Lyon-Sud,
Pierre-Benite, France.
High-dose chemotherapy supported with autologous peripheral stem cell
transplantation is now widely used in the treatment of lymphoma
patients. The benefit of high-dose therapy has been clearly established
after relapse in patients with an aggressive histological subtype who
respond to salvage therapy. However, the use of such treatment also
deserves further evaluation in the first line of therapy in patients
with adverse prognostic factors. In follicular lymphoma, autologous
transplantation seems able to induce long-term responses in selected
clinical situations, but randomized studies are awaited to evaluate the
potential benefit of this approach. In other lymphoma subtypes, the use
of high-dose therapy remains experimental and should still be tested in
clinical trials. Given the feasibility and the limited toxicity of
autologous peripheral stem cell transplantation, the comparison of
different therapeutic strategies (optimal timing, treatments modalities)
will be facilitated and will allow us to assess the best ways of using
this treatment in lymphoma patients.
29
UI - 12196296
AU - Sawadogo D; Lartey MT; Kouassi D; Nacoulma W; Monet D; Sangare A
TI -
[The impact of chemotherapy on haematological and biochemical profiles
during malignant blood diseases in Abidjan, Cote d'Ivoire]
SO - Sante 2002 Apr-Jun;12(2):229-32
AD - Laboratoire d'hematologie, Faculte de pharmacie, Universite de
Cocody-Abidjan, Cote d'Ivoire. education@globeaccess.net
Our research concerned the impact of chemotherapy on the haematological
and biochemical profiles of patients diagnosed with malignant blood
diseases and receiving treatment in Abidjan. The study covered 57
patients, 26 of whom were receiving treatment. Burkitt's lymphoma was
the most common type of malignant blood disease encountered (33%). The
proportion of men was slightly higher, at 54%, and the average age of
patients was 26. Hyperleucocytosis, anaemia and medullar blastosis were
the most common blood disorders. The tumours arising from
hyperleucocytosis and medullar blastosis caused increases in proteins
from inflammatory reaction. The increase was moderate for alpha 1
globulins and haptoglobin and high (at least twice the reference levels)
for C Reactive Protein (CRP) and orosomucoid. Full remission was only
achieved in the cases of Burkitt's lymphoma, in which the haematological
and biochemical parameters reached near-normal levels following
treatment. In cases of chronic myeloid leukaemia the treatment lowered
the hyperleucocytosis but the high rate of CRP might indicate that the
disease was reaching a more acute phase. In the cases of acute
leukaemia, chemotherapy did not achieve full remission: the alpha 1
globulins, including orosomucoids, were the most sensitive proteins to
treatment. Even though the rate of CRP was lowered, it remained high in
all cases of acute leukaemia. Neither haematological nor biochemical
data proved superior to the other in monitoring the effectiveness of the
treatment or the gradual return of the disease. It would be beneficial
to combine them in order to obtain a clearer assessment of the
effectiveness of chemotherapy.
30
UI - 12225489
AU - Bode MK; Tikkakoski T; Johansson J; Johansson K; Kariniemi J;
TI -
Apaja-Sarkkinen M; Tuominen H
Lymphoma of the cervix. Imaging and transcatheter arterial embolization.
SO - Acta Radiol 2002 Jul;43(4):431-2
AD - Department of Radiology, Keski-Pohjanmaa Central Hospital, Kokkola,
Finland.
A case of uterine cervix lymphoma with selective embolization after
angiography is described. Chemotherapy and radiotherapy were carried out
and surgery was avoided.
31
UI - 12094145
AU - Pentimone F; Moncini C; Pastine F; Gerini A; Lucchesi Q
TI -
Spontaneous regression and recurrence of primary low-grade B-cell
gastric lymphoma on the gastric stump 15 and 20 years after
gastroresection.
SO - Panminerva Med 2002 Sep;44(3):271-4
AD - Department of Internal Medicine, Section of Geriatrics, University of
Pisa, Pisa, Italy. l.delcorso@int.med.unipi.it
The recurrence of primary gastric lymphoma (PGL) on the gastric stump
after gastroresection is rare. We describe the case of an 84-year-old
man who had recurrences 15 and 20 years after a Billroth I gastrectomy.
The concordance of the three gastric biopsies showing a low grade B-cell
lymphocytic lymphoma of the mucosa-associated tissue, demonstrated the
recurrence of the disease. The patient has serological evidence of
Helicobacter pylori infection but the eradication therapy had no effect
on the evolution of the disease. The case suggests that PGL is really a
particular entity in the non-Hodgkin's lymphoma group, characterized by
a long spontaneous natural history, with long lasting spontaneous
remissions and recurrences.
32
UI - 12368366
AU - Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ;
TI -
Frenkel A; Ben-Arush M; Gaitini D
Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after
treatment.
SO - J Nucl Med 2002 Oct;43(10):1295-303
AD - Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel.
o_israel@rambam.health.gov.il
The purpose of the present study was to evaluate the role of 67Ga
scintigraphy and CT in treatment monitoring of bone lymphoma. METHODS:
Forty-four lymphoma patients with 91 sites of bone involvement were
evaluated. Eight patients had Hodgkin's disease, and 36 patients had
non-Hodgkin's lymphoma. Thirteen patients had primary lymphoma of the
bone, and 31 patients had secondary lymphoma of the skeleton. 67Ga and
CT studies were performed at baseline, during and at the end of
treatment, and during follow-up. Positive 67Ga studies showed abnormal
uptake in sites of lymphomatous involvement. Positive CT studies showed
lesions with patterns of osteolysis, patterns of osteosclerosis, or a
mixed pattern. A negative 67Ga or CT study showed disappearance of all
lymphoma-related abnormalities. The sensitivity and specificity of 67Ga
scintigraphy at presentation were calculated. Patterns of bone lymphoma
on CT and their treatment-related changes were analyzed and recorded.
Freedom-from-progression (FFP) curves were used to determine the
prognostic value of positive and negative 67Ga and CT findings for
predicting outcome after treatment. RESULTS: The sensitivity of 67Ga for
diagnosis of bone lymphoma was 93%, and the specificity was 91%. A CT
pattern of osteolysis was seen in 70% of skeletal disease sites at
diagnosis and in 21% during follow-up. Osteosclerosis was present in 23%
of sites at diagnosis and in 38% during follow-up. 67Ga findings became
negative in 25% of patients during treatment, whereas only 1 patient
showed negative CT findings. Forty-two percent of patients had negative
67Ga findings at the end of treatment, compared with 18% who had
negative CT findings. Sixty-one percent of patients had negative 67Ga
findings during follow-up, compared with 21% who had negative CT
findings. A statistically significant difference in FFP was found
between patients with positive and negative 67Ga findings at all
evaluated time points. No statistically significant difference in FFP
was found at any time point between patients with positive and negative
CT findings. CONCLUSION: 67Ga scintigraphy has a high sensitivity and
specificity for diagnosis of bone lymphoma. Bone lymphoma may show
osteosclerotic and osteolytic CT patterns at diagnosis, during
treatment, and after treatment. In most patients, CT studies do not
become negative even 1 y after treatment. 67Ga scintigraphy, however,
may be used as a predictor of long-term outcome in patients with
lymphoma of the skeleton.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
